Bristol-Myers Squibb: Psoriasis trials

The registry lists 40 Psoriasis studies with Bristol-Myers Squibb as lead sponsor. 9 are open to participants now and 9 have results posted.

Phase 1 13Phase 2 6Phase 3 8Phase 4 2No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study CompletersNot yet recruitingNCT07791199Phase 3
• Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in ItalyRecruitingNCT07256015
• A Study to Assess Deucravacitinib Safety in PregnancyRecruitingNCT07017699
• A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque PsoriasisRecruitingNCT06979453Phase 3
• A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)RecruitingNCT06701513
• A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)RecruitingNCT06382987
• Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in KoreaRecruitingNCT06258668
• A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque PsoriasisRecruitingNCT05744466
• A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque PsoriasisRecruitingNCT04772079Phase 3
• A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe PsoriasisCompletedNCT05730725Phase 2Results posted
• A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community SettingCompletedNCT05701995Phase 4Results posted
• Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp PsoriasisCompletedNCT05478499Phase 4Results posted
• An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South KoreaCompletedNCT04167462Phase 3Results posted
• An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe PsoriasisCompletedNCT03924427Phase 3Results posted
• Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With PsoriasisCompletedNCT03624127Phase 3Results posted
• An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque PsoriasisCompletedNCT03611751Phase 3Results posted
• A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious PsoriasisTerminatedNCT03329885Phase 1/2Results posted
• Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe PsoriasisCompletedNCT02931838Phase 2Results posted
• A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With PsoriasisActive, not recruitingNCT06952465
• A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their OffspringActive, not recruitingNCT06710470
• A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in JapanCompletedNCT05633264
• A Study to Assess Treatment Patterns, Clinical Outcomes and Healthcare Resource Utilization Among Adult Participants With Moderate-To-Severe Plaque PsoriasisCompletedNCT05547490
• Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice ExperimentCompletedNCT05065762
• A Study of Treatment Patterns and Clinical Outcomes of Psoriasis in JapanCompletedNCT04826536
• Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With PsoriasisCompletedNCT04036435Phase 3
• A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With PsoriasisTerminatedNCT03971825Phase 1
• Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy MalesCompletedNCT03873415Phase 1
• An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male ParticipantsCompletedNCT03419910Phase 1
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type PsoriasisCompletedNCT03337022Phase 1
• The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female PatientsCompletedNCT03262727Phase 1
• A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet FormulationCompletedNCT03254784Phase 1
• Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male ParticipantsCompletedNCT03004768Phase 1
• Safety Study of BMS-986202 in Healthy Subjects and to Treat PsoriasisCompletedNCT02763969Phase 1
• Safety Study of BMS-986165 in Healthy Subjects and to Treat PsoriasisCompletedNCT02534636Phase 1
• Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type PsoriasisTerminatedNCT02502188Phase 1
• A Study of BMS-582949 in Patients With Moderate to Severe Plaque PsoriasisCompletedNCT00399906Phase 2
• Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis VulgarisCompletedNCT00306878Phase 1
• Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis VulgarisCompletedNCT00287547Phase 2
• A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis VulgarisCompletedNCT00277225Phase 1
• Study of BMS-587101 in Patients With Moderate to Severe PsoriasisTerminatedNCT00162253Phase 2